Skip to main content
Top
Published in: Rheumatology International 7/2007

01-05-2007 | Original Article

Effects of pravastatin in murine collagen-induced arthritis

Authors: Toshiaki Yamagata, Koji Kinoshita, Yuji Nozaki, Masafumi Sugiyama, Shinya Ikoma, Masanori Funauchi

Published in: Rheumatology International | Issue 7/2007

Login to get access

Abstract

Here we evaluated whether 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) have beneficial effects for collagen-induced arthritis (CIA). DBA/1 mice were immunized with bovine type-II collagen and administered 100 mg/kg of pravastatin interperitoneally. We measured the effects of pravastatin for CIA including infiltration of macrophages at the synovial membrane and production of anti-type-II collagen antibodies and cytokines. Adverse reactions of pravastatin were also measured. The pravastatin-treated mice had delayed onset of CIA compared with the controls. The involvement of inflammatory cells in the synovial membrane and the expression of monocyte chemotactic protein-1 (MCP-1) mRNA in the joint were reduced. Moreover, some cytokines (TNF-α, IL-6, IFN-γ) and MCP-1 levels in the supernatants of spleen cells cultured with pravastatin decreased. Meanwhile, adverse reactions of pravastatin, such as peritonitis, were not detected. Pravastatin may have good prospects for treating some anti-inflammatory effects on human rheumatoid arthritis.
Literature
1.
go back to reference Feldmann M, Brennan FM, Maini RN (1996) Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 14:397–440PubMedCrossRef Feldmann M, Brennan FM, Maini RN (1996) Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 14:397–440PubMedCrossRef
2.
go back to reference Gracie JA, Forsey RJ, Chan WL, Gilmour A, Leung BP, Greer MR, Kennedy K, Carter R, Wei XQ, Xu D, Field M, Foulis A, Liew FY, McInnes IB (1999) A proinflammatory role for IL-18 in rheumatoid arthritis. J Clin Invest 104:1393–1401PubMedCrossRef Gracie JA, Forsey RJ, Chan WL, Gilmour A, Leung BP, Greer MR, Kennedy K, Carter R, Wei XQ, Xu D, Field M, Foulis A, Liew FY, McInnes IB (1999) A proinflammatory role for IL-18 in rheumatoid arthritis. J Clin Invest 104:1393–1401PubMedCrossRef
3.
go back to reference Yamamura M, Kawashima M, Taniai M, Yamauchi H, Tanimoto T, Kurimoto M, Morita Y, Ohmoto Y, Makino H (2001) Interferon-γ-inducing activity of interleukin-18 in the joint of rheumatoid arthritis. Arthritis Rheum 44:275–285PubMedCrossRef Yamamura M, Kawashima M, Taniai M, Yamauchi H, Tanimoto T, Kurimoto M, Morita Y, Ohmoto Y, Makino H (2001) Interferon-γ-inducing activity of interleukin-18 in the joint of rheumatoid arthritis. Arthritis Rheum 44:275–285PubMedCrossRef
4.
go back to reference Trentham DE, Townes AS, Kang AH (1977) Autoimmunity to type II, collagen: an experimental model of arthritis. J Exp Med 146:857–868PubMedCrossRef Trentham DE, Townes AS, Kang AH (1977) Autoimmunity to type II, collagen: an experimental model of arthritis. J Exp Med 146:857–868PubMedCrossRef
5.
go back to reference Durie FH, Fava RA, Noelle RJ (1994) Collagen-induced arthritis as a model of rheumatoid arthritis. Clin Immunol Immunopathol 73:11–18PubMedCrossRef Durie FH, Fava RA, Noelle RJ (1994) Collagen-induced arthritis as a model of rheumatoid arthritis. Clin Immunol Immunopathol 73:11–18PubMedCrossRef
6.
go back to reference Courtenay JS, Dallman MJ, Dayan AD, Martin A, Mosedale B (1980) Immunization against heterologous type II collagen induces arthritis in mice. Nature 283:666–668PubMedCrossRef Courtenay JS, Dallman MJ, Dayan AD, Martin A, Mosedale B (1980) Immunization against heterologous type II collagen induces arthritis in mice. Nature 283:666–668PubMedCrossRef
7.
go back to reference Stuart JM, Townes AS, Kang AH (1984) Collagen autoimmune arthritis. Ann Rev Immunol 2:199–218CrossRef Stuart JM, Townes AS, Kang AH (1984) Collagen autoimmune arthritis. Ann Rev Immunol 2:199–218CrossRef
8.
go back to reference Inoue I, Goto S, Mizotani K, Awata T, Mastunaga T, Kawai S, Nakajima T, Hokari S, Komada T, Katayama S (2000) Lipophilic HMG-CoA reductase inhibitor has an anti-inflammatory effect Reduction of MRNA levels for interleukin-1β, interleukin-6, cyclooxygenase-2, and p22phox by regulation of peroxisome proliferator-activated receptor α (PPARα) in primary endothelial cells. Life Sci 67:863–876PubMedCrossRef Inoue I, Goto S, Mizotani K, Awata T, Mastunaga T, Kawai S, Nakajima T, Hokari S, Komada T, Katayama S (2000) Lipophilic HMG-CoA reductase inhibitor has an anti-inflammatory effect Reduction of MRNA levels for interleukin-1β, interleukin-6, cyclooxygenase-2, and p22phox by regulation of peroxisome proliferator-activated receptor α (PPARα) in primary endothelial cells. Life Sci 67:863–876PubMedCrossRef
9.
go back to reference Zelvyte I, Dominaitiene R, Crisby M, Janciauskiene S (2002) Modulation of inflammatory mediators and PPARγ and NFκB expression by pravastatin in response to lipoproteins in human monocytes invitro. Pharmacol Res 45:147–154PubMedCrossRef Zelvyte I, Dominaitiene R, Crisby M, Janciauskiene S (2002) Modulation of inflammatory mediators and PPARγ and NFκB expression by pravastatin in response to lipoproteins in human monocytes invitro. Pharmacol Res 45:147–154PubMedCrossRef
10.
go back to reference Romano M, Diomede L, Sironi M, Massimiliano L, Sottocorno M, Polentarutti N, Guglielmotti A, Albani D, Bruno A, Fruscella P, Salmona M, Vecchi A, Pinza M, Mantovani A (2000) Inhibition of monocyte chemotactic protein-1 synthesis by statin. Lab Invest 80:1095–1100PubMed Romano M, Diomede L, Sironi M, Massimiliano L, Sottocorno M, Polentarutti N, Guglielmotti A, Albani D, Bruno A, Fruscella P, Salmona M, Vecchi A, Pinza M, Mantovani A (2000) Inhibition of monocyte chemotactic protein-1 synthesis by statin. Lab Invest 80:1095–1100PubMed
11.
go back to reference Kwak B, Mulhaupt F, Myit S, Mach F (2000) Statins as a newly recognized type of immunomodulator. Nat Med 6:1399–1402PubMedCrossRef Kwak B, Mulhaupt F, Myit S, Mach F (2000) Statins as a newly recognized type of immunomodulator. Nat Med 6:1399–1402PubMedCrossRef
12.
go back to reference Weitz-Schmidt G, Welzenbach K, Brinkmann V, Kamata T, Kallen J, Bruns C, Cottens S, Takada T, Hommel U (2001) Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med 7:687–692PubMedCrossRef Weitz-Schmidt G, Welzenbach K, Brinkmann V, Kamata T, Kallen J, Bruns C, Cottens S, Takada T, Hommel U (2001) Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med 7:687–692PubMedCrossRef
13.
go back to reference Leung BP, Sattar N, Crilly A, Prach M, McCarey DW, Payne H, Madhok R, Campbell C, Gracie JA, Liew FY, McInnes IB (2003) A novel anti-inflammatory role for simvastatin in inflammatory arthritis. J Immunol 170:1524–1530PubMed Leung BP, Sattar N, Crilly A, Prach M, McCarey DW, Payne H, Madhok R, Campbell C, Gracie JA, Liew FY, McInnes IB (2003) A novel anti-inflammatory role for simvastatin in inflammatory arthritis. J Immunol 170:1524–1530PubMed
14.
go back to reference Brackertz D, Mitchell GF, Mackay IR (1977) Antigen-induced arthritis in mice. I. Induction of arthritis in various strains of mice. Arthritis Rheum 20:841–850 Brackertz D, Mitchell GF, Mackay IR (1977) Antigen-induced arthritis in mice. I. Induction of arthritis in various strains of mice. Arthritis Rheum 20:841–850
15.
go back to reference Wood FD, Pearson CM, Tanaka A (1969) Capacity of mycobacterial Wax D and its subfractions to induce adjuvant arthritis in rats. Int Arch Allergy 35:456–467PubMed Wood FD, Pearson CM, Tanaka A (1969) Capacity of mycobacterial Wax D and its subfractions to induce adjuvant arthritis in rats. Int Arch Allergy 35:456–467PubMed
16.
go back to reference Palmer G, Chobaz V, Talabot-Ayer D, Taylor S, So A, Gabay C, Busso N (2004) Assessment of the efficacy of differernt statins in murine collagen-induced arthritis. Arthritis Rheum 50:4051–4059PubMedCrossRef Palmer G, Chobaz V, Talabot-Ayer D, Taylor S, So A, Gabay C, Busso N (2004) Assessment of the efficacy of differernt statins in murine collagen-induced arthritis. Arthritis Rheum 50:4051–4059PubMedCrossRef
17.
go back to reference John S, Jacobi J, Delles C, Schlaich MP, Schneider M, Schmieder RE (2000) Rapid improvement of endothelial function after lipid-lowering therapy with cerivastatin within two weeks. J Am Cardiol 35:256A John S, Jacobi J, Delles C, Schlaich MP, Schneider M, Schmieder RE (2000) Rapid improvement of endothelial function after lipid-lowering therapy with cerivastatin within two weeks. J Am Cardiol 35:256A
18.
go back to reference Kurakata S, Kada M, Shimada Y, Komai T, Nomoto K (1996) Effects of different inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, pravastatin sodium and simvastatin, on sterol synthesis and immunological functions in human lymphocytes in vitro. Immunopharmacol 34:51–61CrossRef Kurakata S, Kada M, Shimada Y, Komai T, Nomoto K (1996) Effects of different inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, pravastatin sodium and simvastatin, on sterol synthesis and immunological functions in human lymphocytes in vitro. Immunopharmacol 34:51–61CrossRef
19.
go back to reference Lu B, Rutledge BJ, Gu L, Fiorillo J, Lukacs NW, Kunkel SL, North R, Gerard C, Rollins BJ (1998) Abnormalities in monocyte recruitment and cytokine expression in monocyte chemoattractant protein 1-deficient mice. J Exp Med 187:601–608PubMedCrossRef Lu B, Rutledge BJ, Gu L, Fiorillo J, Lukacs NW, Kunkel SL, North R, Gerard C, Rollins BJ (1998) Abnormalities in monocyte recruitment and cytokine expression in monocyte chemoattractant protein 1-deficient mice. J Exp Med 187:601–608PubMedCrossRef
20.
go back to reference Chinetti G, Fruchart JC, Staels B (2000) Peroxisome proliferator-activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation. Inflamm Res 49:497–505PubMedCrossRef Chinetti G, Fruchart JC, Staels B (2000) Peroxisome proliferator-activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation. Inflamm Res 49:497–505PubMedCrossRef
21.
go back to reference Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK (1998) The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation. Nature 391:79–82PubMedCrossRef Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK (1998) The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation. Nature 391:79–82PubMedCrossRef
22.
go back to reference Devchand PR, Keller H, Peters JM, Vazquez M, Gonzalez FJ, Wahli W (1996) The PPARα-leukotriene B4 pathway to inflammation control. Nature 384:39–43PubMedCrossRef Devchand PR, Keller H, Peters JM, Vazquez M, Gonzalez FJ, Wahli W (1996) The PPARα-leukotriene B4 pathway to inflammation control. Nature 384:39–43PubMedCrossRef
23.
go back to reference Nezasa K, Higaki K, Matsumura T, Inazawa K, Hasegawa H, Nakano M, Koike M (2002) Liver-specific distribution of rosuvastatin in rats: comparison with pravastain and simvastatin. Drug Metab Dispos 30:1158–1163PubMedCrossRef Nezasa K, Higaki K, Matsumura T, Inazawa K, Hasegawa H, Nakano M, Koike M (2002) Liver-specific distribution of rosuvastatin in rats: comparison with pravastain and simvastatin. Drug Metab Dispos 30:1158–1163PubMedCrossRef
24.
go back to reference Yamzaki M, Suzuki H, Hanano M, Tokui T, Komai T, Sugiyama Y (1993) Na+-independent multispecific anion transporter mediates active transport of pravastatin into rat liver. Am Physiol Soc 264:G36–G44 Yamzaki M, Suzuki H, Hanano M, Tokui T, Komai T, Sugiyama Y (1993) Na+-independent multispecific anion transporter mediates active transport of pravastatin into rat liver. Am Physiol Soc 264:G36–G44
25.
go back to reference Yada T, Nakata M, Shiraishi T, Kakei M (1999) Inhibition by simvastatin, but not pravastatin, of glucose-induced cytosolic Ca2+ signaling and insulin secretion due to blockade of L-type Ca2+ channels in rat islet β-cells. Br J Pharmacol 126:1205–1213PubMedCrossRef Yada T, Nakata M, Shiraishi T, Kakei M (1999) Inhibition by simvastatin, but not pravastatin, of glucose-induced cytosolic Ca2+ signaling and insulin secretion due to blockade of L-type Ca2+ channels in rat islet β-cells. Br J Pharmacol 126:1205–1213PubMedCrossRef
26.
go back to reference Kanda M, Satoh K, Ichihara K (2003) Effects of atorvastatin and pravastatin on glucose tolerance in diabetic rats mildly induced by streptozotocin. Biol Pharm Bull 26:1681–1684PubMedCrossRef Kanda M, Satoh K, Ichihara K (2003) Effects of atorvastatin and pravastatin on glucose tolerance in diabetic rats mildly induced by streptozotocin. Biol Pharm Bull 26:1681–1684PubMedCrossRef
27.
go back to reference Chamberlian LH (2001) Inhibition of isoprenoid biosynthesis causes insulin resistance in 3T3-L1 adipocytes. FEBS Lett 507:357–361CrossRef Chamberlian LH (2001) Inhibition of isoprenoid biosynthesis causes insulin resistance in 3T3-L1 adipocytes. FEBS Lett 507:357–361CrossRef
28.
go back to reference Sever PS, Dahlf B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O’Brian E, Östergren J (2003) Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial–Lipid Lowering Arm (ASCOT–LLA): a multicentre randomised controlled trial. Lancet 361:1149–1158PubMedCrossRef Sever PS, Dahlf B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O’Brian E, Östergren J (2003) Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial–Lipid Lowering Arm (ASCOT–LLA): a multicentre randomised controlled trial. Lancet 361:1149–1158PubMedCrossRef
29.
go back to reference Jackson G (1997) Drug points: simvastatin and impotence. BMJ 315:31 Jackson G (1997) Drug points: simvastatin and impotence. BMJ 315:31
30.
go back to reference Halkin A, Lossos IS, Mevorach D (1996) HMG-CoA reductase inhibitor-induced impotence. Ann Pharmacother 30:192PubMed Halkin A, Lossos IS, Mevorach D (1996) HMG-CoA reductase inhibitor-induced impotence. Ann Pharmacother 30:192PubMed
31.
go back to reference Hyyppa MT, Kronholm E, Virtanen A, Leino A, Jula A (2003) Does simvastatin affect mood and steroid hormone levels in hypercholesterolemic men? A randomized double-blind trial. Psychoneuroendocrinology 28:181–194PubMedCrossRef Hyyppa MT, Kronholm E, Virtanen A, Leino A, Jula A (2003) Does simvastatin affect mood and steroid hormone levels in hypercholesterolemic men? A randomized double-blind trial. Psychoneuroendocrinology 28:181–194PubMedCrossRef
Metadata
Title
Effects of pravastatin in murine collagen-induced arthritis
Authors
Toshiaki Yamagata
Koji Kinoshita
Yuji Nozaki
Masafumi Sugiyama
Shinya Ikoma
Masanori Funauchi
Publication date
01-05-2007
Publisher
Springer-Verlag
Published in
Rheumatology International / Issue 7/2007
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-006-0270-9

Other articles of this Issue 7/2007

Rheumatology International 7/2007 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.